• Теги
    • избранные теги
    • Компании319
      • Показать ещё
      Страны / Регионы106
      • Показать ещё
      Разное96
      • Показать ещё
      Формат10
      Международные организации8
      Показатели10
      • Показать ещё
      Издания3
      Люди8
      • Показать ещё
Выбор редакции
Выбор редакции
25 апреля, 13:06

Fresenius близка к приобретению Akorn

Согласно информации из осведомленных источников, немецкая компания сектора здравоохранения Fresenius SE & Co. близка к заключению сделки по приобретению американского производителя дженериков Akorn. При этом сообщается, что в рамках сделки Fresenius может выплатить более $4 млрд наличными. Заметим, что в сентябре прошлого года Fresenius заключила самую крупную в истории деятельности компании сделку, выкупив испанскую частную сеть больниц Quironsalud за 5,8 млрд евро ($6,14 млрд), включая долг. Что же касается сделки с Akorn, то она позволит немецкой фирме увеличить годовые продажи подразделения по выпуску лекарств примерно на $1 млрд.

25 апреля, 11:40

Фондовые индексы Европы стабильны во вторник у максимума за 2 года

Фондовые индексы стран Западной Европы слабо меняются в начале торгов во вторник после значительного роста накануне.

Выбор редакции
25 апреля, 10:02

Fresenius близка к приобретению Akorn

Согласно информации из осведомленных источников, немецкая компания сектора здравоохранения Fresenius SE & Co. близка к заключению сделки по приобретению американского производителя дженериков Akorn. При этом сообщается, что в рамках сделки Fresenius может выплатить более $4 млрд наличными. Заметим, что в сентябре прошлого года Fresenius заключила самую крупную в истории деятельности компании сделку, выкупив испанскую частную сеть больниц Quironsalud за 5,8 млрд евро ($6,14 млрд), включая долг. Что же касается сделки с Akorn, то она позволит немецкой фирме увеличить годовые продажи подразделения по выпуску лекарств примерно на $1 млрд.

Выбор редакции
15 апреля, 04:10

Arkansas Courts Put Seven Executions On Hold

By Steve Barnes LITTLE ROCK, Ark. (Reuters) - The state of Arkansas on Friday ran into a pair of new legal obstacles to its plan to carry out lethal injections on seven murderers in an unprecedented series of executions before the end of the month. The Arkansas Supreme Court granted an emergency stay of execution for Bruce Ward, 60, who was convicted of killing a convenience store clerk, and less than two hours later the executions of six other murderers were put on hold when an Arkansas circuit judge issued a temporary restraining order. The judge’s restraining order barred the state from administering one of three drugs it planned to use in the executions, which are scheduled to begin on Monday and stretch over 11 days. Attorney General Leslie Rutledge plans to file an emergency request for the Supreme Court to vacate that order, a spokesman said, allowing the injections to commence. The state, which has not carried out an death sentence in 12 years, scheduled the fast-paced executions in order to beat the expiration date on its batch of one of the drugs used in its lethal injection cocktail. An eighth inmate who had been scheduled to die also won a stay earlier, removing him from the list for April execution. Lawyers for all of the convicts have asked a federal court in Little Rock to block the executions, arguing the state’s rush to the death chamber was unconstitutional and reckless. The U.S. judge has yet to issue a ruling on the broader case. The state Supreme Court offered no comment in staying Ward’s execution. His lawyers had argued he was schizophrenic and the court should take that into consideration before any final decision on his execution. “He deserves a day in court for that, but in Arkansas the rules do not permit that,” Scott Braden, a lawyer with the Arkansas Federal Defender Office, said after the stay was granted. The attorney general was evaluating how to proceed in Ward’s case, a spokesman said in a statement. Arkansas uses potassium chloride in combination with vecuronium bromide and midazolam. The latter drug is intended to render the inmate unconscious before the other two chemicals are administered to paralyse the lungs and stop the heart. Governor Asa Hutchinson has said the state must act quickly because the efficacy date for midazolam expires at the end of the month. But Judge Wendell Griffen, an outspoken opponent of capital punishment, issued an order blocking the state from using a second drug, vecuronium bromide, after a petition from its maker, McKesson Medical-Surgical Inc. The company said the Arkansas prison system failed to return a supply of the drug when it learned the state intended to use it for executions, a violation of an understanding between the two, according to McKesson. “As a public opponent of capital punishment, Judge Griffen should have recused himself from this case,” said Judd Deere, spokesman for the attorney general. Two other drug makers on Thursday asked a federal court to block Arkansas from using their drugs for upcoming executions, claiming that doing so would violate contractual controls and create a public health risk, court documents showed. The companies did not disclose which of their drugs Arkansas will use during the executions.   (Additional reporting by Brendan O’Brien in Milwaukee and Jon Herskovitz in Austin, Texas; Writing by Frank McGurty; Editing by Cynthia Osterman and Bill Trott) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

14 апреля, 14:24

2 Companies Intervene To Block Their Drugs In 'Assembly Line' Arkansas Executions

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); Two pharmaceutical companies are asking a federal judge to stop Arkansas from using their drugs in the planned execution of seven men in 11 days this month. The European-owned Fresenius Kabi USA and West-Ward Pharmaceuticals Corp. filed a friend of the court brief in support of a lawsuit by inmates because they’re opposed to their drugs being used in capital punishment. “The use of the medicines in lethal injections runs counter to the manufacturers’ mission to save and enhance patients’ lives, and carries with it not only a public-health risk, but also reputational, fiscal and legal risks,” the companies said in their brief.  The drugs’ use in executions is a breach of the companies’ “supply chain” controls, argues the brief, which was filed Thursday. The manufacturers “sell only to wholesalers and distributers who agree to resell only to acute-care hospitals, clinics, and healthcare facilities,” and the drugs were never intended to be used in executions, it states. “The only conclusion is that these medicines were acquired from an unauthorized seller in violation of important contractual terms that the manufacturers relied on,” the companies added. In addition, using drugs for capital punishment “creates a public-health risk because it could result in the denial of medicines from patients who need them most,” the brief stated. Arkansas hasn’t executed anyone in more than a decade. Now officials plan to begin with a double execution on Monday and finish executions on April 27. (An eighth man, Jason McGehee, won a reprieve.) One defense attorney blasted the schedule as an “assembly line” execution, Reuters reported. The state is reportedly rushing to kill the men before its supply of the controversial sedative midazolam used in executions runs out at the end of April. The drug has been implicated in botched executions in Ohio, Arizona and Oklahoma. Arkansas officials won’t say where they obtained the drugs they intend to use, but Fresenius Kabi is suspected of manufacturing the potassium chloride — which stops the heart — planned for the executions. And The Associated Press reports that West-Ward is the likely source of the midazolam the state plans to use. type=type=RelatedArticlesblockTitle=Related Coverage + articlesList=58ef6880e4b0bb9638e1abfa,58e3c687e4b0d0b7e1650ef5,58cabc2be4b0e0d348b34110 -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

14 апреля, 14:24

2 Companies Intervene To Block Their Drugs In 'Assembly Line' Arkansas Executions

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); Two pharmaceutical companies are asking a federal judge to stop Arkansas from using their drugs in the planned execution of seven men in 11 days this month. The European-owned Fresenius Kabi USA and West-Ward Pharmaceuticals Corp. filed a friend of the court brief in support of a lawsuit by inmates because they’re opposed to their drugs being used in capital punishment. “The use of the medicines in lethal injections runs counter to the manufacturers’ mission to save and enhance patients’ lives, and carries with it not only a public-health risk, but also reputational, fiscal and legal risks,” the companies said in their brief.  The drugs’ use in executions is a breach of the companies’ “supply chain” controls, argues the brief, which was filed Thursday. The manufacturers “sell only to wholesalers and distributers who agree to resell only to acute-care hospitals, clinics, and healthcare facilities,” and the drugs were never intended to be used in executions, it states. “The only conclusion is that these medicines were acquired from an unauthorized seller in violation of important contractual terms that the manufacturers relied on,” the companies added. In addition, using drugs for capital punishment “creates a public-health risk because it could result in the denial of medicines from patients who need them most,” the brief stated. Arkansas hasn’t executed anyone in more than a decade. Now officials plan to begin with a double execution on Monday and finish executions on April 27. (An eighth man, Jason McGehee, won a reprieve.) One defense attorney blasted the schedule as an “assembly line” execution, Reuters reported. The state is reportedly rushing to kill the men before its supply of the controversial sedative midazolam used in executions runs out at the end of April. The drug has been implicated in botched executions in Ohio, Arizona and Oklahoma. Arkansas officials won’t say where they obtained the drugs they intend to use, but Fresenius Kabi is suspected of manufacturing the potassium chloride — which stops the heart — planned for the executions. And The Associated Press reports that West-Ward is the likely source of the midazolam the state plans to use. type=type=RelatedArticlesblockTitle=Related Coverage + articlesList=58ef6880e4b0bb9638e1abfa,58e3c687e4b0d0b7e1650ef5,58cabc2be4b0e0d348b34110 -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
10 апреля, 10:38

Fresenius может приобрести Akorn

Немецкая компания сектора здравоохранения Fresenius заявила в пятницу, 7 апреля, о том, что ведет переговоры о поглощении американского производителя дженериков Akorn, при этом отмечается, что сделка может и вовсе не состояться. Финансовые и прочие условия потенциальной сделки пока не сообщаются. Заметим, что в сентябре прошлого года Fresenius заключила самую крупную в истории деятельности компании сделку, выкупив испанскую частную сеть больниц Quironsalud за 5,8 млрд евро ($6,14 млрд), включая долг. Стоит отметить, что на фоне данных новостей бумаги Akorn укрепились в ходе пятничной сессии на 18%, а рыночная капитализация компании достигла таким образом $3,7 млрд.

Выбор редакции
10 апреля, 09:06

Fresenius может приобрести Akorn

Немецкая компания сектора здравоохранения Fresenius заявила в пятницу, 7 апреля, о том, что ведет переговоры о поглощении американского производителя дженериков Akorn, при этом отмечается, что сделка может и вовсе не состояться. Финансовые и прочие условия потенциальной сделки пока не сообщаются. Заметим, что в сентябре прошлого года Fresenius заключила самую крупную в истории деятельности компании сделку, выкупив испанскую частную сеть больниц Quironsalud за 5,8 млрд евро ($6,14 млрд), включая долг. Стоит отметить, что на фоне данных новостей бумаги Akorn укрепились в ходе пятничной сессии на 18%, а рыночная капитализация компании достигла таким образом $3,7 млрд.

Выбор редакции
Выбор редакции
07 апреля, 21:47

Akorn shares jump 19% after report Germany's Fresenius mulling a bid

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Выбор редакции
07 апреля, 16:49

Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital

Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.

Выбор редакции
20 марта, 16:05

Fresenius (FMS) to Jointly Develop Acumen with Epic Systems

Fresenius Medical Care AG & Co. KGAA (FMS) announced that it would jointly develop Acumen 2.0 with Epic Systems Corporation.

17 марта, 01:12

Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

Выбор редакции
02 марта, 17:53

New Strong Sell Stocks for March 2nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

23 февраля, 18:04

Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat

Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.

Выбор редакции